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Background & objectives: Most group A streptococcal (GAS) vaccine strategies focused on the surface M
protein of the GAS.  However, vaccine based on M protein have some drawbacks.  In the present study,
we used two approaches to identify new proteins and peptides that may have utility as vaccine candidates.
Methods: A whole gel elution procedure was used to separate GAS surface antigens into 9 size
fractionated pools.  Mice were vaccinated with each pool and antibody titre, opsonic ability and protective
capacity measured. In an alternative approach BioInformatics was used to identify putative GAS
surface proteins. Peptides from within these proteins were then selected on the basis of predicted
antigenicity or location. These peptides were conjugated to keyhole lymphocyanin (KLH) and
immunogenicity measured in a mouse model.
Results: One pool of GAS surface proteins (approximately 29kDa) induced antibodies that were both
opsonic and potentially protective.  Immunoflourescent  microscopy demonstrated that these antibodies
bound to the surface of M1 GAS.  Amino acid sequencing subsequently identified superoxide dismutase
as the major antigen in this pool. A BioInformatic search of the M1 GAS genome and subsequent
analysis identified several peptides that fulfilled criteria as potential vaccine candidates.  Each peptide
when conjugated to KLH was able to induce a strong antibody response.
Interpretation & conclusion: Several new antigens were identified that may have potential as vaccine
targets. A future GAS  vaccine may have multiple peptide epitopes, providing protection against
multiple GAS strains.
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Streptococcus pyogenes or group A streptococcus
(GAS) is a human bacterial pathogen that colonises the
throat or skin surfaces of the host.  GAS infection may
result in a number of diseases including pharyngitis
(classical ‘strep throat’), impetigo and less commonly
necrotising fasciitis among others. If treated ineffectively,
the post-streptococcal sequelae acute rheumatic fever
(ARF) and acute glomerulonephritis may develop. ARF
in its severest form leads to the potentially fatal rheumatic
heart disease (RHD). While the incidence of rheumatic
fever and serious GAS infection remains low in
developed countries, there has been an increase in the
number of cases reported since the mid 1980s1.  Of
greater concern is the prevalence of GAS infection and
ARF in the developing countries. Rheumatic fever is a
leading cause of heart disease in children in these
regions2,3.
Most group A streptococcal vaccine strategies have
focused on the surface M protein, a major virulence
factor of GAS4,5. Antibodies to the amino terminus of
the M protein have been shown to be opsonic and provide
protection against challenge from homologous organisms;
i.e., they are type specific. However, vaccines based on
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the M protein face two major obstacles.  Firstly, the amino
terminus of the M protein is highly antigenically variable.
There are greater than 100 reference GAS emm types
and an increasing number of which are not M
serotypable.  Antibodies to the serotypic specific amino
termini are therefore ineffective in providing broad
spectrum protection against multiple GAS strains.
Secondly, some epitopes from the M protein are known
to be immunologically cross-reactive with heart proteins
and possibly contribute towards the pathology of RHD3,6.
Current strategies in utilising the M protein as a vaccine
involve the use of multiple N-termini and/or defined
epitopes within the conserved carboxyl C-region that are
not cross-reactive with host tissues7,8. Apart from the
M protein only a few antigens are under development
as potential GAS vaccine candidates. These include
GAS carbohydrate, C5a peptidase and cysteine
protease9-11.
 We hypothesised that GAS vaccine antigens should
be surface exposed. They should also be immunogenic,
and ideally induce opsonic antibody responses. In the
present study two approaches were used for the
identification of non M protein streptococcal antigens
that may have potential as vaccine candidates. The first
involved the screening of pools of GAS surface proteins
for antigens that invoked antibodies with properties
desirable in a GAS vaccine. The second involved the
use of BioInformatics to predict antigenic peptides
encoded by open reading frames found in the M1 GAS
genome.
Material & Methods
Preparation of cell surface extracts: M1 GAS was
grown overnight in Todd Hewitt broth. Extracts of M1
GAS surface proteins were prepared using mutanolysin
digestion as described12,13. Surface protein extracts were
then separated by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) and
isolated into individual fractions using a whole gel eluter
(Bio-Rad, USA).
Selection of peptides: Many surface proteins of Gram-
positive bacteria have a characteristic ‘LPxTG’ amino
acid motif in the C-terminal region.  Surface proteins
additionally generally have an export signal sequence
that can be used to predict whether a protein is
transported to the bacterial cell surface14.  The M1 GAS
genome has 1,752 putative protein encoding regions15.
Using a BioInformatical approach all 1,752 open reading
frames were analysed for the presence of an ‘LPxTG’
motif (or close homologue) and export signal motif. A
number of proteins were identified with one or both of
these motifs, termed ‘putative surface proteins (PSPs).
It was hypothesised that the amino terminus would be
the most immunologically exposed portion of the
molecule. Consequently, the amino terminus of the
predicted mature PSP (i.e., excluding putative signal
sequence) was analysed for the presence of antigenic
amino acid sequences as predicted by computational
algorithms and peptides from these regions were
synthesised. Where algorithms failed to identify
sequences of high antigenicity, peptides corresponding
to the extreme amino terminus (ex signal sequence) of
the PSP were synthesised. The peptides used in this
study are listed in Table I.
Immunological protocols: Outbred Quackenbush mice
(n=5) were subcutaneously immunized with antigen
following established protocols.  In the case of peptides,
antigens were first conjugated to keyhole lymphocyanin
Table I. Peptides used in this study
Peptide Putative protein function Genbank accession no.
ACHNTSKPSNTDSVFSLTGK unknown AAK33302.1
AQNFRNIMHGSDSFFYTFTS putative ABC transporter, permease protein AAK34838.1
CSTLVEKDVAPKDELEMLAW putative membrane protein AAK34293.1
ESVLQAQMAAQQLPVIGGIA putative sortase AAK34025.1
LEALADQTDALQSEEAAVVK protein GRAB AAK34185.1
QEVFSLVKEPILKQTQASSS Unknown AAK33772.1
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(KLH). The primary immunization consisted of antigen
emulsified in phosphate buffered saline (PBS).  Boosts
were delivered in PBS. Qualitative ELISA and
opsonisation assays were performed as previously
described16.  Immunofluorescent assays were carried
out essentially as described7 with an additional step in
which cells were preincubated with human
immunoglobulin to inhibit the non-specific binding of
antigen-specific antisera by Ig binding proteins and Fc-
binding receptors on the surface of GAS17.
Results
Identification of immunogenic antigens in pooled
protein fractions: M1 GAS surface protein extract
prepared by mutanolysin digestion were size fractionated
by SDS-PAGE whole gel elution. Neighbouring fractions
containing proteins of similar size were then pooled to
give a total of 9 groups (defined as Pool A to Pool I)
with each pool containing several proteins.  The molecular
weight of the protein in these pools ranged from
approximately 20 to 78 kDa. Each of the pools was used
to subcutaneously immunize mice and antibody response
measured via an indirect ELISA against the whole M1
GAS surface protein extract (Table II).  All Pools invoked
a strong antibody response, with antibody titres from mice
within some pools exceeding the range of the experiment
(titres >3.3x106). At the highest dilution used in the
ELISA, optical density was greatest against pool B and
pool D antisera.
All antibodies were subsequently tested for their ability
to bind to the surface of GAS, to opsonise GAS and to
protect vaccinated mice against subsequent GAS
challenge (Table II). Immunoflourescent microscopy
showed that antisera raised against each of the pools
bound to the surface of GAS (as compared to normal
mouse sera). Antisera raised against pool G elicited the
most intense fluorescence, with pools E and F also
showing a high degree of fluorescence. Pools F and G
antisera showed the highest level of opsonic ability (58
and 62% respectively) with the difference between these
two pools not statistically significant. To investigate the
level of protection conveyed by antibodies raised to the
pooled fractions, mice were challenged with 400µl of
passaged M1 GAS (3x103 cfu/ml), and monitored over
a 10-day period. After 10 days, 40 per cent of the PBS
immunized mice and 80 per cent of mice immunized with
a positive control antigen were protected from challenge.
Mice immunized with pool G exhibited the greatest level
of protection from M1 GAS challenge, with 100 per cent
survival.  Pools D, E, and F also showed high levels of
protection (>75%). Due to the low numbers of mice
within each group, differences in murine survival between
groups were found not to be statistically significant.
The data suggests that pool G elicits contain a surface
antigen that showed antibody responses which were both
opsonic and potentially protective. The size of the major
antigen in this pool was approximately 29 kDa. Amino
acid sequencing identified this antigen as superoxide
dismutase (SOD). This antigen is a known virulence
factor of many bacteria18.
Immunoreactivity of peptide conjugates: ELISA was
used to measures peptide specific antibody responses
for each of the peptides used in this study (Fig.).  The
mean titre for LEA20-KLH and QEV20-KLH when
measured against there respective  peptides was greater
than 2x106. In contrast titres to AQN20-KLH was only
4300 ± 1700.  As some peptides are known not to adhere
to microtitre plates, AQN20 antibody titres were next
measured against AQN20 linked to diphtheria toxoid
(DT). The titres of AQN20 against AQN2-DT was
Table II. Properties of surface fractions and induced antibodies
Pool
A B C D E F G H I
Molecular weight (kDa) 78 60 55 40 35 31 29 23 20
Opsonic activity (%) 42 41 39 45 36 58 62 17 6
Immunofluorescence* + + + ++ ++ ++ +++ + +
Challenge  (% survival) 40 40 60 75 80 80 100 60 40
*Relative fluorescence; +, low fluorescence; ++, medium fluorescence; +++, high fluorescence
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found to be greater than 1.3x106. The average titre in
this group against DT was only 300.
Discussion
We used two approaches for the identification of
antigens that may be of use as potential GAS vaccine
candidates. Screening of pools of proteins purified from
the surface of GAS identified SOD as a potential vaccine
candidate.  This approach had the benefit of directly
testing many antigens for properties that are considered
desirable in a vaccine (e.g., opsonic ability).  A potential
drawback was that each pool contained a number of
antigens, each of which might partially contribute to
protection. Additionally proteins present in low abundance
in the surface extracts, or not expressed in the bacterial
growth conditions used may be overlooked in this system.
Nevertheless this approach identified SOD as a potential
GAS vaccine candidate.  This enzyme is a major virulence
determinant in other bacteria18-20, and has also been
shown to induce protective immune responses21-23. SOD
is also highly conserved across streptococci24 and
inactivation of this gene has been shown to severely limit
the growth capacity of GAS25. We are currently assessing
the utility of recombinantly expressed SOD to induce
antibody responses which are opsonic and protective.
The use of purified antigens overcomes many of the
limitations of the above method. The use of peptides
instead of whole protein also minimises the amino acid
sequence in a vaccine candidate, reducing the chance
of engendering host cross-reactive antibodies. We
hypothesised that peptides derived from proteins located
on the surface of GAS are exposed to the host immune
system. Using BioInformatics  six peptides were
identified with this profile and found to be immunogenic
in mice. We are currently testing these antibodies in
opsonisation experiment against several GAS strains. A
future GAS vaccine may contain multiple peptide
epitopes, providing protection against broad multiple GAS
strains.
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